Infectious Disease Clinical Trial
— BAbAROfficial title:
Better Antibiotic Prescribing Through Action Research
NCT number | NCT03082521 |
Other study ID # | BAbAR |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 1, 2017 |
Est. completion date | January 1, 2022 |
Verified date | May 2022 |
Source | Universiteit Antwerpen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
This PAR (participatory action research) study to improve antibiotic prescribing quality in a GPC (general practitioner cooperative) during OOH-care (out-of-hours-care) uses a mixed methods approach using qualitative as well as quantitative techniques. In a first exploratory phase we will work on partnership development and mapping the existing issues. In a second phase the focus will be on facilitating change and implementing interventions through PDSA (plan do study act) cycles. In a third phase outcomes on prescribing quality during and outside office hours will be evaluated. Equally important is the process evaluation and theory building on improving antibiotic prescribing through PAR.
Status | Completed |
Enrollment | 170 |
Est. completion date | January 1, 2022 |
Est. primary completion date | March 15, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - GPs working in the GPC Exclusion Criteria: - / |
Country | Name | City | State |
---|---|---|---|
Belgium | GPC Brabo | Antwerp |
Lead Sponsor | Collaborator |
---|---|
Universiteit Antwerpen |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Interview study | Semi-structured interview with the stakeholders on the experiences of prescribing antibiotics in OOH care and the willingness to participate in PAR. | year 1 | |
Primary | Antibiotic prescribing feedback using antibiotic prescribing quality indicators | Using antibiotic prescribing quality indicators (APQI) feedback on the antibiotic prescription rates of the GPC will be generated. For the six most common indications for antibiotic prescribing (in descending order: acute bronchitis (ICPC (6) code R78), acute upper RTI (R74), cystitis/other urinary infection (UTI; U71), acute tonsillitis (R76), acute/chronic sinusitis (R75), and acute otitis media (H71)) and for pneumonia (R81) values of three valid antibiotic prescribing quality indicators (APQI)quality indicators will be calculated and fed back: (5)
= the percentage of patients with age and/or gender limitation prescribed an antibiotic; = a. and receiving the guideline recommended antibiotic; = a and receiving quinolones. |
year 1 | |
Primary | Ethnographic study: explanatory and descriptive approach of observations, descriptions and interpretation of the phenomenon of prescribing antibiotics in OOH care | Observations of consultations to get a better understanding of the context , difficulties, clinical issues, etc. of prescribing antibiotics in OOH care. | year 2 | |
Primary | Focus groups (descriptative & interpretative) & description of PDSA cycles on developing and implementing interventions on antibiotic prescribing in OOH care | Qualitative and quantitative results of phase 1 will be fedback to the group of GPs. In reflective peer group sessions the issues and problems will be explored and interventions will be designed taking into account previous work.
The implemented interventions and changes will be studied based on both outcome as process indicators. ESACs' Antibiotic Prescribing Quality Indicators (APQI) will be used to assess quality of antibiotic prescribing. Pocess indicators will depend on the chosen interventions. |
year 3 | |
Primary | Process evaluation and sociological meso-theory building of PAR in the case of improving antibiotic prescribing behaviour in a GPC | Evaluation of the study, theory building on optimising antibiotic use with PAR. Study of group-level interactions, descriptive. | year 4 | |
Secondary | Use of Antibiotics (quantity, type, use of broad-spectrum antibiotics,etc.) in daytime care | The use of antiobiotics during office hours to assess any spill over effect of PAR in OOH-care. | year 5 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05568953 -
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
|
Phase 2 | |
Completed |
NCT04568889 -
Minnesota COVID-19 Testing Project
|
N/A | |
Completed |
NCT06063330 -
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
|
Phase 1 | |
Completed |
NCT01198925 -
Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion
|
Phase 4 | |
Completed |
NCT05063812 -
Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
|
||
Not yet recruiting |
NCT03636711 -
Antibiotic Stewardship in Infectious Disease Departement
|
||
Completed |
NCT03457688 -
Effect of Prebiotic Fructans to Reduce Number of Febrile Infections in Children
|
N/A | |
Completed |
NCT03241355 -
Prebiotic Fructans on the Incidence of Acute Infectious Diseases in Children
|
N/A | |
Terminated |
NCT05420077 -
Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273
|
Phase 1 | |
Completed |
NCT04084106 -
Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota
|
Phase 4 | |
Recruiting |
NCT05013944 -
AnovaOS Network Powered Patient Registry
|
||
Completed |
NCT03893279 -
Perception of Smell and Taste During Antibiotic Treatment
|
||
Active, not recruiting |
NCT05619770 -
Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects
|
Phase 1 | |
Completed |
NCT01772901 -
Brief Influenza Vaccine Education to Pregnant Women
|
N/A | |
Completed |
NCT05413772 -
Temocillin in ESBL-Enterobacteriaceae Infections
|
||
Completed |
NCT04319328 -
Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
|
||
Completed |
NCT04613271 -
Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
|
Phase 3 | |
Completed |
NCT03239665 -
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
|
N/A | |
Completed |
NCT03224026 -
Validation of a Proteomic Signature and Assessment of Viremia in Children With Fever Without Source
|
||
Not yet recruiting |
NCT06102070 -
Genetic Susceptibility to Severe Infections
|